Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond S Douglas

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Eye (London, England)|December 22, 2018
Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosisRaymond S Douglas
Aesthetic Surgery Journal|August 21, 2018
Commentary on: Simultaneous Aesthetic Eyelid Surgery and Orbital Decompression for Rehabilitation of Thyroid Eye Disease: The One-Stage ApproachRaymond S Douglas
Current Opinion in Ophthalmology|July 7, 2011
The pathophysiology of thyroid eye disease: implications for immunotherapyRaymond S Douglas, Shivani Gupta
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 15, 2012
Orbital and periorbital infectionsCesar Briceno, Raymond S Douglas
Facial Plastic Surgery : FPS|May 10, 2003
A systematic comprehensive approach to management of irreversible facial paralysisRaymond S Douglas, Roberta E Gausas
Nature Reviews. Endocrinology|August 3, 2011
Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy?Terry J Smith, Raymond S Douglas
The New England Journal of Medicine|May 14, 2020
Teprotumumab for Active Thyroid Eye Disease. ReplyRaymond S Douglas, George J Kahaly
Therapeutics and Clinical Risk Management|December 10, 2019
Thyroid Eye Disease: How A Novel Therapy May Change The Treatment ParadigmYao Wang, Amy Patel, Raymond S Douglas
American Journal of Ophthalmology|August 5, 2019
A New Era in the Treatment of Thyroid Eye DiseaseAmy Patel, Huasheng Yang, Raymond S Douglas
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|May 14, 2014
The pathophysiology of thyroid eye diseaseShannon J C Shan, Raymond S Douglas
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Eye (London, England)|December 22, 2018
Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosisRaymond S Douglas
Aesthetic Surgery Journal|August 21, 2018
Commentary on: Simultaneous Aesthetic Eyelid Surgery and Orbital Decompression for Rehabilitation of Thyroid Eye Disease: The One-Stage ApproachRaymond S Douglas
Current Opinion in Ophthalmology|July 7, 2011
The pathophysiology of thyroid eye disease: implications for immunotherapyRaymond S Douglas, Shivani Gupta
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 15, 2012
Orbital and periorbital infectionsCesar Briceno, Raymond S Douglas
Facial Plastic Surgery : FPS|May 10, 2003
A systematic comprehensive approach to management of irreversible facial paralysisRaymond S Douglas, Roberta E Gausas
Nature Reviews. Endocrinology|August 3, 2011
Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy?Terry J Smith, Raymond S Douglas
The New England Journal of Medicine|May 14, 2020
Teprotumumab for Active Thyroid Eye Disease. ReplyRaymond S Douglas, George J Kahaly
Therapeutics and Clinical Risk Management|December 10, 2019
Thyroid Eye Disease: How A Novel Therapy May Change The Treatment ParadigmYao Wang, Amy Patel, Raymond S Douglas
American Journal of Ophthalmology|August 5, 2019
A New Era in the Treatment of Thyroid Eye DiseaseAmy Patel, Huasheng Yang, Raymond S Douglas
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|May 14, 2014
The pathophysiology of thyroid eye diseaseShannon J C Shan, Raymond S Douglas
Pageof 12